Charlotte Nichols MP told Psychedelic Alpha that, based on her recent conversations with the current Home Office Minister with responsibility for drugs policy, Dame Diana
I am thrilled to share that I will be moderating a Table Topic on the impact of psychedelics legalization on trademark law at the International
*** Josh Hardman, Psychedelic Alpha: Can you share further information about the study? Aaron Wolfgang: The project is currently titled A Randomized, Double-Blind, Placebo-Controlled Clinical
No previous pharmaceutical playbook presents a perfect model for psychedelic medicalization due to the unique combination of 1) their Schedule I placement; 2) their long
Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common Side EffectsFebruary 17, 2025 Psychedelic Alpha’s Josh Hardman interviews Common Side Effects co-creator Steve
In this Issue Q4’24: Federal Psychedelics Lobbying Update GH Research Discusses Lack of Placebo Effect, Decision to Keep Trial Sites Secret Virginia Lawmakers Question Purpose
VANCOUVER, BC, Feb. 14, 2025 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral
Table of Contents No DEA waiver for psilocybin under Right to Try On February 13, 2025, in another setback for common sense drug policy, the
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment
VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical